Previous 10 | Next 10 |
(Source: Evil Speculator) Anyone thinking 2018 investing hasn’t been anything other than a proverbial roller-coaster ride needs their sanity checked. Thankfully, the end of the year is fast approaching, and if given the option to choose - bull or bear - I would have, and did, opt for ...
2018 seems to be ending on a bad note in the markets. December is setting the wrong kind of records, and Q4 has been a bumpy one in general. This is what happens in the stock market sometimes, but it's been easy to forget over the decade-long bull market. We're using the end of the year as a...
NEW YORK, NY / ACCESSWIRE / December 10, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Global Blood Therapeutics , Inc. (NASDAQ: GBT) , a clinical-stage bioph...
"In chaos, there is fertility. " - Anais Nin Today, we revisit Global Blood Therapeutics ( GBT ) . This stock has had an up and down year as can be seen from the chart below. The shares have recently been on an upswing despite the current horrid sentiment in the market. The company jus...
NEW YORK, NY / ACCESSWIRE / December 4, 2018 / U.S. markets closed up on Monday as the U.S. and China came to an agreement of a 90-day trade war truce at the G-20 meeting in Argentina. The Dow Jones Industrial Average jumped 1.13 percent to close at 25,826.43, while the S&P 500 Index inc...
Global Blood Therapeutics ( GBT +55.7% ) is up on more than an 8x surge in volume on the heels of positive data from a Phase 3 clinical trial, HOPE , evaluating voxelotor in patients at least 12 years old with sickle cell disease (SCD). The results were presented at ASH in San Diego. ...
More news on: Tesaro, Global Blood Therapeutics, Atossa Genetics, Inc., Stocks on the move, , Read more ...
Interim Analysis of Data from 1500 mg Cohort of HOPE-KIDS 1 Study Consistent with Phase 3 HOPE- Results in Demonstrating Improvement in Hemoglobin and Clinical Measures of Hemolysis and Favorable Safety in Pediatric Patients Company to Host Investor Webcast Today, Monday, December 3, ...
Tesaro (NASDAQ: TSRO ) +59% on acquisition by Glaxo for $75. More news on: Tesaro, Global Blood Therapeutics, Hudson Technologies, Inc., Stocks on the move, , Read more ...
FDA agrees with Global Blood Therapeutics' (NASDAQ: GBT ) proposal relating to use of an accelerated approval pathway for voxelotor for the treatment of sickle cell disease (SCD). More news on: Global Blood Therapeutics, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Global Blood Therapeutics Inc. Company Name:
GBT Stock Symbol:
NASDAQ Market:
Global Blood Therapeutics Inc. Website:
Guerbet to Spotlight the Novel New Drug Elucirem™ (gadopiclenol) injection at the 2022 Radiological Society of North America Scientific Assembly and Annual Meeting PR Newswire Join us at Booth #1711 Opportunity to learn about the recently US FDA-approved nov...
The healthcare industry is growing at an unprecedented rate, and healthcare stocks are poised to benefit from this growth. This is large because healthcare companies are developing innovative new treatments and technologies that are transforming the way we care for our health. As a resu...
NEW YORK, NY / ACCESSWIRE / September 22, 2022 / New York, New York-Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: EVO Payments...